share_log

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

genmab將在摩根士丹利第22屆全球醫療保健大會上進行新聞發佈
GlobeNewswire ·  08/26 12:26

Media Release
COPENHAGEN, Denmark; August 26, 2024

媒體發佈
丹麥哥本哈根;2024年8月26日

Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 PM EDT / 7:05 PM CEST on September 4, 2024. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab's website at .

Genmab A/S (納斯達克: GMAB)宣佈,其首席執行官Jan van de Winkel博士和首席財務官Anthony Pagano將於2024年9月4日下午1:05在摩根士丹利第22屆全球醫療保健年會上進行一場爐邊對話。 該活動的網絡直播將包括簡短的開場致辭,以及問答環節,屆時將在Genmab's網站上提供。

About Genmab
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines.

Genmab是一家國際生物技術公司,其核心目標是引導其不可阻擋的團隊致力於改善患者生活,爲此不斷創新和研發不同的抗體治療方法。25年來,其充滿激情、創新和協作的團隊發明了下一代抗體技術平台,並利用轉化、定量和數據科學來推進項目進展,包括雙特異性T細胞激動劑、抗體藥物聯用、下一代免疫檢查點調節劑和增強功效功能的抗體。到2030年,Genmab的願景是利用令人驚歎的抗體藥物改善癌症和其他嚴重疾病患者的生活。
Genmab是一家國際生物技術公司,其核心目標是引導不可阻擋的團隊努力改善具有創新性和差異化的抗體治療藥物的患者生活。25年來,Genmab的充滿激情、創新和協作的團隊發明了下一代抗體技術平台,並利用翻譯、定量和數據科學,形成了包括雙特異T細胞結合劑、抗體藥物聯用治療、下一代免疫檢查點調節劑和增強效應功能抗體在內的專有藥物流水線。到2030年,Genmab的願景是通過炫酷的抗體藥物(KYSO)改變癌症和其他嚴重疾病患者的生活。

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

聯繫人:Marisol Peron,高級副總裁,全球通信和企業事務 電話:+1 609 524 0065;電子郵件:mmp@genmab.com Andrew Carlsen,副總裁,投資者關係負責人 電話:+45 3377 9558;電子郵件:acn@genmab.com

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Brian Siegel,IRC,MBA-高級管理董事,Hayden IR,電話:(346)396-8696,ir@zedge.net
Marisol Peron,全球通信和企業事務高級副總裁
電話:+1 609 524 0065;電子郵件:mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Media Release contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Andrew Carlsen,投資者關係負責人
電話:+45 3377 9558;電子郵件:acn@genmab.com
本公告包含前瞻性聲明。"相信"、"期望"、"預計"、"意圖"和"計劃"等類似表達方式均爲前瞻性聲明。根據這些聲明,實際結果或表現可能與此類聲明中表達或暗示的未來結果或表現有所不同。導致我們實際結果或表現有所不同的重要因素包括,但不限於,與產品的臨床前和臨床開發有關的風險,包括意想不到的安全問題,與產品製造有關的不確定性,我們產品缺乏市場接受度,我們無法管理增長,以我們業務領域和市場的競爭環境,我們無法吸引和保留合適的人員,我們專利和專有權利的不可執行性或缺乏保護,我們與關聯實體的關係、技術的變化和發展,可能使我們的產品或技術過時,以及其他因素。有關這些風險的進一步討論,請參見Genmab最近的財務報告中的風險管理部分,可在之上獲取,並在Genmab的最新20-F年度報告和在美國證券交易委員會(SEC)的其他申報文書中包括的風險因素,可在www.sec.gov上獲取。 Genmab不承擔更新或修訂本媒體發佈中的前瞻性聲明的責任,也不確認此類聲明反映之後實現的事件或情況,除非法律要求。

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; HexaBody; DuoHexaBody, HexElect and KYSO.

Genmab A/S及/或其子公司擁有以下商標:Genmab; Y形狀的Genmab標誌; Genmab結合Y形狀的標誌; HuMax; DuoBody; HexaBody; DuoHexaBody、HexElect和KYSO。

Media Release no. i13
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122


CVR 編號2102 3884
LEI代碼529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

genmab A/S
Carl Jacobsens Vej 30
2500瓦爾比
丹麥

Attachment

附件

  • 240826_MRi13_Genmab to Present at Morgan Stanley

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論